What do systematic reviews say?

Summary of findings for NSAIDs plus corticosteroids vs corticosteroids

The review found no eligible studies for this question.

• Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for NSAIDs plus corticosteroids vs corticosteroids

The review found no eligible studies for this question.

• Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for NSAIDs plus corticosteroids vs corticosteroids

The review found no eligible studies for this question.

• Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for NSAIDs plus corticosteroids vs corticosteroids

Summary of findings for NSAIDs plus corticosteroids showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids alone (moderate certainty).

• Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
  RR 1.07 [0.98, 1.16]
  1 study · 138 participants
  Moderate

Summary of findings table: photocoagulation of drusen vs control

The review found no eligible studies for this question.

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table: photocoagulation of drusen vs control

Summary of findings table: photocoagulation of drusen showed no clear difference in development of CNV compared with control (high certainty).

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  OR 1.07 [0.79, 1.46]
  11 studies · 2159 participants
  High

Summary of findings table: photocoagulation of drusen vs control

Summary of findings table: photocoagulation of drusen showed no clear difference in development of geographic atrophy compared with control (low certainty).

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  OR 1.3 [0.38, 4.51]
  2 studies · 148 participants
  Low

Summary of findings table: photocoagulation of drusen vs control

Summary of findings table: photocoagulation of drusen showed no clear difference in visual loss of 2‐3+ lines of visual acuity compared with control (moderate certainty).

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  OR 0.99 [0.81, 1.22]
  9 studies · 2002 participants
  Moderate

Summary of findings table: photocoagulation of drusen vs control

Summary of findings table: photocoagulation of drusen showed no clear difference in loss of ≥ 0.3 log units of contrast sensitivity compared with control (low certainty).

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  OR 0.82 [0.2, 3.31]
  1 study · 82 participants
  Low

Summary of findings table: photocoagulation of drusen vs control

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table: photocoagulation of drusen vs control

Summary of findings table: photocoagulation of drusen leads to higher drusen reduction compared with control (high certainty).

• Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration 2015 · Cochrane Headline outcomes only
  OR 9.16 [6.28, 13.4]
  3 studies · 570 participants
  High

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

It is very uncertain whether summary of findings: intravitreal anti‐VEGF plus intravitreal steroid changes significant intraocular inflammation at compared with intravitreal anti‐VEGF (very low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 0.53 [0.05, 5.08]
  Studies not reported
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher development of cataract at compared with intravitreal anti‐VEGF (moderate certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 7.49 [2.87, 19.6]
  Studies not reported
  Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher raised intraocular pressure at compared with intravitreal anti‐VEGF (moderate certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 8.13 [4.67, 14.16]
  Studies not reported
  Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 1.32 [0.61, 2.86]
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found